Ann Arbor-based Pipex Pharmecueticals Inc. has leased space to
manufacture its leading drug candidate that will be used to treat
neurological diseases such as Alzheimer's.
Excerpts:
The company plans to establish an in-house neuroscience sales and marketing department to market the drug next year.
According to a recent SEC filing, the company leased a
6,000-square-foot facility in Ann Arbor in January and plans to
manufacture Coprexa initially at the site. Kanzer said the company
would release details - including the location - in late April.
Since September 2005, the 11-employee firm has had a collaborative
research and development agreement with the University of Michigan,
from which it also exclusively licenses a patent relating to
anti-copper therapeutics.
It also has agreements with several other institutions, including
McLean Hospital at Harvard University, the University of Southern
California and Children's Hospital-Boston.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.